
In a phase 2 international trial (LITESPARK-015), belzutifan demonstrated antitumor activity in 72 patients with advanced pheochromocytoma or paraganglioma. Objective response was 26% and disease control 85%, with median progression-free survival of 22.3 months. The treatment also reduced antihypertensive medication needs, with manageable safety.
Like
Save
Share